Investor Alert

New York Markets After Hours

Topics

Science and Technology

Video

China's Next Economic Transformation: Going Carbon Neutral by 2060

  • China's Next Economic Transformation: Going Carbon Neutral by 2060 China's Next Economic Transformation: Going Carbon Neutral by 2060 6:04
10:30 a.m. Sept. 15, 2021 - By Victor Reklaitis
Biden to announce deal with U.K., Australia on sharing defense technology: reportsPresident Joe Biden on Wednesday will announce a new effort with the U.K. and Australia to share advanced defense technologies in a bid to counter China, according to reports from and . The White House said Biden is due to speak at 5 p.m. Eastern on a "national security initiative," and he will be joined virtually by U.K. Prime Minister Boris Johnson and Australian Prime Minister Scott Morrison.
2:45 a.m. Aug. 20, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily average of COVID-19 cases, deaths and hospitalization rise to multi-month highsThe global tally for the coronavirus-borne illness climbed above 210 million as of early Friday, while death toll rose to 4,404,511, according to . The U.S. led the world with a total of 37.29 million cases and 625,166 deaths. The daily average of new cases over the past seven days rose to 143,827 as of Thursday, up 44% from two weeks ago and the most since Feb. 1, according to . The daily average for deaths increased to 911, up 108% in two weeks, and the most since March 31, while hospitalizations of 86,877 was up 53% from two weeks ago and the most since Feb. 9. The number of people that have been fully vaccinated rose to 169.59 million, or 51.1% of the total U.S. population, according to . AstraZeneca PLC said Friday that in a late stage trial. "There were no cases of severe Covid-19 or Covid-19-related deaths in those treated with AZD7442," the company said.
7:49 a.m. Aug. 16, 2021 - By Tomi Kilgore
Pfizer, BioNTech submit trial data on COVID-19 booster shot to FDAPfizer Inc. and partner BioNTech SE announced Monday that data from a Phase 1 study has been submitted to the U.S. Food and Drug Administration, for the evaluation of a third, booster dose of their COVID-19 vaccine. The companies said they will also submit the data to the European Union's version of the FDA, the European Medicines Agency, as well as other regulatory authorities, in the coming weeks. In the U.S., Pfizer-BioNTech plan to seek licensure of a third dose in people at least 16 years old. Last week, for some people with compromised immune systems. "This initial data indicate that we may preserve and even exceed the high levels of protection against the wild-type virus and relevant variants using a third dose of our vaccine," said BioNTech Chief Executive Ugur Sahin. "A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season." Shares of Pfizer slipped 0.6% in midday trading and BioNTech's stock dropped 10.6%, while the S&P 500 eased 0.4%.
7:15 a.m. Aug. 16, 2021 - By Tomi Kilgore
CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primatesShares of CureVac N.V. gained 0.4% in morning trading Monday, but bucked the selloff in the biotechnology sector and the broader stock market, after the Germany-based company revealed upbeat preclinical data regarding its vaccine candidates against the coronavirus that causes COVID-19, in non-human primates. The stock's gain comes as the iShares Biotechnology ETF dropped 2.4% and the S&P 500 slid 0.7%. The first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, were developed in collaboration with U.K.-based drug maker GlaxoSmithKline PLC and is based on mRNA technology, the same in the COVID-19 vaccines developed by Moderna Inc. and Pfizer Inc. and BioNTech SE . GlaxoSmithKline's stock eased 0.1% in morning trading. The company said CV2CoV achieved better activation of immune responses, with higher antibody neutralizing capacity across all variants, including the delta variant. "The current study shows that the immune responses and resulting protection produced by our second-generation candidate, based on our mRNA technology featuring targeted optimizations, are substantially improved in non-human primates against both the original SARS-CoV-2 virus as well as the Beta and Delta Variants of Concern and the Lambda Variant of Interest," said CureVac Chief Scientific Officer Dr. Igor Splawski.
5:04 a.m. July 1, 2021 - By Jaimy Lee
Novavax's experimental COVID-19 shot has 86.4% efficacy against the Alpha variantShares of Novavax Inc. were up 2.5% in premarket trading on Thursday, the day after The New England Journal of Medicine published a looking at how Novavax's COVID-19 vaccine candidate performed in a Phase 3 clinical trial conducted in 15,000 participants in the U.K. An earlier analysis of the data was previously published as a preprint. According to the new study, Novavax's experimental vaccine has an overall efficacy rate of 96.4% against the original strain of the virus and an 86.3% efficacy rate against the Alpha variant, which was first identified in the U.K. and has been the most dominant form of the virus in many countries since the start of the year. Novavax did not mention the Delta variant, which is now the most dominant form of the virus in the U.K., in this study. The company is conducting separate studies of its experimental shot in the U.S. Novavax's stock is up 90.4% for the year, while the broader S&P 500 has gained 14.4%.
5:29 a.m. June 21, 2021 - By Jaimy Lee
Day One Biopharma's experimental glioma drug gets an orphan designation in EuropeShares of Day One Biopharmaceuticals Inc. gained 9.4% in premarket trading on Monday after the company said its experimental glioma treatment received an orphan designation in Europe. The drug candidate has already received a Breakthrough Therapy designation from U.S. regulators for one indication and an orphan designation as a treatment for malignant glioma. In the U.S., an orphan-drug designation supports developing treatments for diseases that affect fewer than 200,000 people. Gliomas are a type of nervous system tumor. Day One last month.
3:55 a.m. June 16, 2021 - By Jaimy Lee
Regeneron says its COVID-19 antibody treatment cuts the risk of death among hospitalized patientsShares of Regeneron Pharmaceuticals Inc. gained 0.1% in premarket trading on Wednesday after the company said its COVID-19 antibody therapy cut the risk of death in patients who have been hospitalized by 20%. This is the first time clinical research has demonstrated that Regeneron's antibody treatment has improved survival for hospitalized patients. The study, which is being conducted in the U.K. in patients who have not yet developed antibodies, follows other research that showed the company's antibody treatment can improve recovery times among people with mild or moderate forms of the disease. Regeneron said it is planning to ask the Food and Drug Administration to expand the emergency-use authorization in the U.S. to include these types of patients. Regeneron's stock is up 9.2% so far this year, while the broader S&P 500 has gained 13.0%.
5:36 a.m. June 15, 2021 - By Jaimy Lee
Novavax says efficacy of COVID-19 vaccine isn't affected when co-administered with the flu shotShares of Novavax Inc. were down 0.9% in trading on Tuesday, the day after the company said a study evaluating co-vaccination against COVID-19 and the flu demonstrated similar efficacy to administering Novavax's experimental COVID-19 shot alone. "Separate health care visits to cover both COVID-19 and influenza vaccinations will be burdensome," a Novavax executive said in a news release. As part of the Phase 3 clinical trial for its coronavirus vaccine in the U.K., the company also enrolled 431 participants in a sub-study that gave participants both the COVID-19 vaccine and the flu shot. In the , published Sunday, the researchers found that the immunogenicity of the flu shot was the same, while there was a "modest decrease" in the immunogenicity of the COVID-19 shot. Novavax also announced this week that its coronavirus vaccine when it comes to preventing symptomatic infection in roughly 30,000 participants enrolled in the Phase 3 clinical trial in the U.S. Novavax's stock has soared 86.2% so far this year, while the S&P 500 is up 13.3%.
3:55 a.m. June 11, 2021 - By Tomi Kilgore
Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeShares of Orphazyme A/S plunged 50.2% in active premarket trading Friday, , after the Denmark-based biopharmaceutical company said overnight that wasn't aware of any reason for the recent "extreme volatility." Trading volume was already up to 4.1 million shares before Friday's open, compared with the full-day average over the past 30 days of about 286,000 shares, according to FactSet On Thursday, the stock had soared as much 1,387% intraday before closing up 301.5% on volume of 7.9 million shares, and was halted a total of 22 times for volatility during the day. "The company is not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume that has occurred since June 10, 2021," the company said in a statement. "Investors who purchase the company's ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines." The company's applications for arimoclomol for Niemann-Pick disease type C are under priority review with the U.S. Food and Drug Administration, with an expected action date of June 17. Even with the previous day's surge, the stock has gained 62.9% over the past three months through Thursday, while the S&P 500 has gained 7.6%.
9:32 a.m. May 25, 2021 - By Tomi Kilgore
Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billionShares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboration with Roche Holding AG's Genentech that could be valued at more than $1.4 billion. Trading volume spiked to a record 205.7 million shares, enough to make the stock the most actively traded on major U.S. exchanges, and compared with the full-day average of about 576,200 shares, according to FactSet. The collaboration and license agreement with Genentech is to discover, develop and commercialize respiratory and ophthalmology therapies using Pieris's Anticalin technology. Under terms of the collaboration, Pieris will receive an upfront payment of $20 million, and is eligible to receive more than $1.4 billion in additional milestone payments plus royalties for commercialized programs. Pieris recorded revenue of $29.3 million in 2020, down from $46.3 million in 2019. Pieris' part in the collaboration is discovery research and early preclinical development of the programs, while Genentech will be responsible for investigational new drug (IND)-enabling activities, clinical development and commercialization. The stock has now gained 16.4% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 0.9% and the S&P 500 has advanced 11.8%.
10:49 a.m. April 27, 2021 - By Jaimy Lee
Novavax's stock jumps after Biden mentions its COVID-19 vaccine candidateShares of Novavax Inc. gained 12.1% in trading on Tuesday after President Joe Biden mentioned that the company's experimental COVID-19 vaccine may be nearing emergency-use authorization in the U.S. "The problem is right now we have to make sure we have other vaccines like Novavax and others coming on," he said during a speech. "And I think we'll be in a position to be able to share vaccines with other countries who are in real need. That's the hope and expectation." Novavax's still-investigational COVID-19 vaccine is currently being tested in a Phase 3 clinical trial in Mexico and the U.S. that began in December. (A separate late-stage study in the U.K. is also underway, and early data from that trial found that the vaccine candidate had an overall efficacy rate of 89.7%.) Novavax's stock has soared 126.0% so far this year, while the S&P 500 is up 11.5%.
3:59 a.m. April 21, 2021 - By Jaimy Lee
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemiaVertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia. The companies previously set up a development deal in 2015; as part of the amended one, which was announced Tuesday, Vertex will pay the Swiss genome-editing company a new $900 million upfront payment, with an additional $200 million available for meeting regulatory milestones, to test the investigational therapy for the blood disorders. In exchange, Vertex will provide 60% of costs and get 60% of profits from future sales if the therapy is approved and commercialized. Since the start of the year, Vertex's stock is down 6.8%, shares of Crispr Therapeutics have dropped 20.5%, and the S&P 500 is up 10.1%.
4:44 a.m. April 16, 2021 - By Jenny Strasburg
J&J privately asked rival COVID-19 vaccine makers to probe clotting risks AstraZeneca was interested in joining forces to investigate the safety issue and communicate vaccine benefits and risks, but Pfizer and Moderna didn’t see the need for group actionJohnson & Johnson privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Moderna Inc. declined.
2:25 a.m. April 12, 2021 - By Tomi Kilgore
Coronavirus tally: Global deaths from COVID-19 climb toward 3 million, as U.S. death toll tops 562,000The global tally for the coronavirus-borne illness rose to 136.1 million on Monday, according to , as the death toll climbed to 2,937,730. The U.S. leads the world in cases and deaths by wide margins, with 31.2 million cases, or about 23% of the global total, while the 562,066 death toll made of about 19% of the total. On Sunday, the U.S. added at least 48,147 new cases and 296 new deaths, , although those numbers are likely under-reported given reduced staffing at hospitals at weekends. The U.S. has averaged 69,632 cases per day, up 11% from the average two weeks ago. The rise in new cases comes despite the continued increase in vaccinations. More than 187.0 million doses have been administered and more than 119.2 million Americans -- 35.9% of the total population -- have received at least one dose, with more than 72.6 million people, or 21.9% of the population, being fully vaccinated, according to (CDC). Outside of the U.S., Brazil is second globally in cases at 13.53 million and also second with a death toll of 353,137. India is third worldwide in cases with 13.48 million and fourth in deaths at 170,179. Mexico is third by deaths at 209,338 and 14th highest by cases at 2.3 million. The U.K. has 4.38 million cases and 127,331 deaths, the highest in Europe and fifth highest in the world.
1:12 p.m. March 24, 2021 - By Andrew Keshner
Equal Pay Day: How paid-leave and child-care policies failed to close gender pay gap Women typically need at least one extra degree to earn as much as their male colleaguesWomen typically need at least one extra degree to earn as much as their male colleagues.
2:19 a.m. March 19, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily case count climbs above 60,000, as the total count approaches 30 millionWhile COVID-19-related restrictions continue to be lifted, the daily number of confirmed cases of the coronavirus that causes COVID-19 has increased for a third-straight day. There were at least 60,782 new cases on Thursday, according to , up from 58,856 on Wednesday, while the daily death toll increased to at least 1,549 from 1,177 the day before. The global tally rose to 121,848,070 as of Friday morning, according to , with the U.S. accounting for 24.3% of the cases with 29,667,305. The global death toll grew to 2,692,244, with the U.S. toll of 539,698 accounting for 20.0%. On the vaccine front, the showed that 151,108,445 vaccine doses have been delivered and 115,730,008 doses have been administered. There have been 75,495,716 people, or 22.7% of the U.S. population, who have received at least one vaccine dose, while 40,981,464 people, or 12.3% of the population, have been fully vaccinated. Outside of the U.S., Brazil is second globally in cases at 11,780,820 and also second with a death toll at 287,499. India is third worldwide in cases with 11,514,331 and fourth in deaths at 159,370.
2:27 a.m. March 18, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily case count rises to nearly 59,000, while deaths slip to less than 1,200The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed to 121,256,160 as of Thursday morning, according to , with the U.S. accounting for 24.4% of the cases with 29,607,486. The global death toll grew to 2,681,790, while the U.S. death count rose to 538,087, or 20.1% of the worldwide total. In the U.S., new cases rose to at least 58,856 on Wednesday, according to , from 54,437 on Tuesday, while the number of deaths slipped to 1,177 from 1,245. On the vaccine front, the latest showed that 147,590,615 vaccine doses have been delivered and 113,037,627 doses have been administered. There have been 73,669,956 people, or 22.2% of the U.S. population, who have received at least one vaccine dose, while 39,989,196 people, or 12.0% of the population, have been fully vaccinated. Outside of the U.S., Brazil is second globally in cases at 11,698,838 and also second with a death toll at 284,775. India is third worldwide in cases with 11,474,605 and fourth in deaths at 159,216.
2:23 a.m. March 17, 2021 - By Tomi Kilgore
Coronavirus tally: Daily U.S. deaths rise above 1,200 as new cases slipThe global tally for confirmed cases of the coronavirus that causes COVID-19 climbed to 120,745,792 as of Wednesday morning, , with the U.S. accounting for 24.5% of the cases with 29,549,556. The global death toll grew to 2,671,764, while the U.S. death count rose to 536,922, or 20.1% of the worldwide total. On Tuesday, the number of new cases fell to at least 54,437 from 57,081 on Monday, while deaths increased to 1,245 people from 751 the day before, . For vaccines, show that 142,918,525 vaccine doses have been delivered and a total of 110,737,856 doses have been administered. There have been 72,135,616 people who have received at least one dose, or 21.7% of the population, and 39,042,345 people, or 11.8% of the population, have been fully vaccinated. Outside of the U.S., Brazil has the second highest death toll at 282,127 and is second by cases at 11,603,535. India is third worldwide in cases with 11,438,734 million and fourth in deaths at 159,044.
2:28 a.m. March 16, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily case and death tally edges up, but average for the week falls 18%The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed to 120,273,942 on Tuesday, according to , with the U.S. accounting for nearly one-quarter of the cases with 29,495,422. The global death toll grew to 2,662,067, while the U.S. death count rose to 535,628, or one-fifth of the worldwide total. On Monday, new cases increased to at least 57,081 from 38,034 on Sunday, and deaths rose to at least 751 people from 572 the day before, . The daily average of new cases over the past week was 55,153, down 18% from the average two weeks earlier. On the vaccine front, the show that 135,847,835 vaccine doses have been delivered, while 109,081,860 arms have been jabbed, including 71,054,445 people who have received at least one dose and 38,335,432 people who have been fully vaccinated. Outside of the U.S., Brazil has the second highest death toll at 279,286 and is second by cases at 11,519,609. India is third worldwide in cases with 11,409,831 million and fourth in deaths at 158,856. Mexico has the third highest death toll at 194,944 and 13th highest case tally at 2,167,729. The U.K. has the fifth-most cases at 4,276,840, while the death toll of 125,817 is fifth highest in the world and the highest in Europe.
6:45 a.m. March 9, 2021 - By Tomi Kilgore
Second Sight Medical stock soars nearly 1,000% in 3 daysShares of Second Sight Medical Products Inc. shot up 30.7% to $15.38 on volume of 56.6 million shares in morning trading Tuesday, bringing its three-day gain to 975.5%, in the wake of the company's announcement that for the treatment of retinitis pigmentosa. The stock skyrocketed a record 304.9% on record volume of 739.7 million shares on March 5 after the announcement, then 103.3% on volume of 320.4 million shares on Monday, before Tuesday's gain. The stock had closed at a near 3-month low of $1.43 prior to the rally. On Tuesday, the stock had been up as much as 69.9% at an intraday high of $20.00, the highest price seen since February 2018, before paring gains. Separately, Paris-based Pixium Vision S.A. saying the business combination with Second Sight announced on Jan. 6 continues. At that time, an agreement with the developer of bionic vision systems in which Second sight will raise at least $25 million in working capital, Pixium will contribute to Second Sight certain assets in exchange for newly issued Second Sight common stock and Second Sight will transfer its Orion Assets to a newly formed subsidiary, which will be partially spun off to Second Sight shareholders. Second Sight's stock has advanced 339.4% over the past 12 months, while the S&P 500 has gained 41.6%.
6:47 a.m. Feb. 22, 2021 - By Jaimy Lee
Novavax completes enrollment in Phase 3 clinical trial for its COVID-19 vaccine candidateShares of Novavax Inc. were down 6.2% in trading on Monday after the company said it had completed enrollment of the Phase 3 clinical trial for its COVID-19 vaccine candidate in Mexico and the U.S. Novavax said that 20% of the roughly 30,000 trial participants are LatinX, 13% are African Americans, 6% are Native Americans, and 5% are Asian Americans. Separately, 13% of all trial participants are 65 years old or older. Novavax's experimental vaccine requires two doses, spaced 21 days apart. The company last month from a late-stage trial of the same vaccine that is being conducted in the United Kingdom. Novavax's stock has soared 3,289.1% over the past 12 months, while the broader S&P 500 is up 15.3%.
4:02 a.m. Feb. 12, 2021 - By Jaimy Lee
CureVac's stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.Shares of CureVac gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine is currently being tested in a Phase 3 clinical trial in Europe and Latin America. CureVac's stock has soared 64.4% over the past three months, while the S&P 500 is up 9.6%.
10:03 a.m. Feb. 8, 2021 - By Jaimy Lee
UniQure's stock rallies 7% on positive safety data for Huntington's disease treatmentShares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. UniQure said it expects to enroll six more patients who have been diagnosed with the rare neurodegenerative disease by mid-2021. The investigational gene therapy is called AMT-130. "While early, we remain bullish about uniQure's [Huntington's disease] gene therapy and continue to believe the program is nearly all upside from current levels," Raymond James analyst Danielle Brill wrote in a note to investors. Uniqure's stock is down 35.9% for the past year, while the broader S&P 500 has gained 16.5%.
11:04 a.m. Feb. 1, 2021 - By Jaimy Lee
Bank of America downgrades Moderna stock over concerns about valuationShares of Moderna Inc. tumbled 8.2% in trading on Monday after Bank of America analysts downgraded the company's stock to underperform from neutral, citing valuation concerns. Until December, Moderna was a clinical-stage company that had yet to bring to market a single therapy, but it now has one of two authorized COVID-19 vaccines in the U.S. The company's stock is up 52.7% so far this year and has soared 677.6% over the past 12 months. Moderna "shares continue to run...attaining levels that are increasingly difficult to justify on a fundamental basis," the Bank of America analysts wrote in a Feb. 1 note to investors. They estimate that Moderna's COVID-19 vaccine will have about 14% of the COVID-19 vaccine market in the U.S. and Europe, and it will generate peak sales of $12.8 billion in 2022, a sales figure that is expected to decline to less than $1 billion by 2027. The emergence of two other viable COVID-19 vaccine candidates, which are being developed by Johnson & Johnson and Novavax Inc. , also cut into analyst expectations, though neither experimental vaccine has received emergency use authorization from the Food and Drug Administration or has so far reported efficacy rates as high as Moderna or BioNTech SE /Pfizer Inc.'s vaccines. "The number of vaccine options with compelling characteristics (single injection, lower cost, clean safety) could begin to weigh on Moderna's margins and market share longer-term," Bank of America analysts concluded. The S&P 500 is up 13.5% over the last 12 months.
3:51 a.m. Jan. 27, 2021 - By Jaimy Lee
Regeneron says its COVID-19 antibody cocktail still works against new strains in lab testShares of Regeneron Pharmaceuticals Inc. gained 1.2% in premarket trading on Wednesday after the company said its COVID-19 antibody cocktail still works against two new more infectious strains of the virus: the B.1.1.7 and the B.1.351. The company worked with researchers at Columbia University to assess how the drug, which has received emergency authorization in the U.S., works against the new strains in a laboratory, according to a preprint published Wednesday. (A preprint is a type of preliminary study.) The study was not conducted in humans. Regeneron said its antibody cocktail, made up of imdevimab and casirivimab, remained effective against the B.1.1.7 strain, but casirivimab's potency was reduced against the B.1.351 strain, which was first identified in South Africa. It has not yet tested the cocktail against the P.1 strain that has emerged from Brazil. Close to 300 people in the U.S. have confirmed cases with the B.1.1.7 strain, which was first detected in the United Kingdom, and the first case of P.1. in the U.S. was identified this week in Minnesota. The B.1.351 has not yet been detected in the U.S. BioNTech SE /Pfizer Inc. and Moderna Inc. also ran similar studies evaluating if their vaccines can protect against the new variants. Regeneron's stock has rallied 60.3% over the past year, while the S&P 500 is up 16.8%.
10:33 a.m. Jan. 25, 2021 - By Ciara Linnane
Biden to reinstate travel bans amid fears about new variants as global case tally heads toward 100 million Dr. Fauci says Johnson & Johnson’s one-dose vaccine could bet emergency use authorization within two weeksThe global tally of confirmed cases of the coronavirus-borne illness COVID-19 headed closer to 100 million on Monday with the U.S. accounting for a quarter of that total, as President Joe Biden prepared to reinstate travel restrictions against foreign citizens visiting the U.S. from Brazil, the U.K, Ireland and much of the rest of Europe, as well as South Africa.
4:55 a.m. Jan. 25, 2021 - By Jaimy Lee
Moderna: Lab study confirms its COVID-19 vaccine still protects against new variantsShares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. The study was not conducted in humans. The findings were released in a news release, and the company said it expects the results to be published in preprint form. Moderna said the in-vitro studies showed that the B.1.1.7 variant had no "significant" impact on neutralizing antibody titers developed as a result of vaccination; however, they also demonstrated that the vaccine was less effective against the B.1.351 variant. In this case, the vaccine still produced levels of neutralizing antibody titers that were protective, but the titer levels were lower. Moderna said it now plans to study booster doses for its two-dose COVID-19 vaccine, to see if a third dose of some kind can increase neutralizing antibody titers and if a booster can specifically protect against the B.1.351 variant. This booster, mRNA-1273.351, will be tested in preclinical studies and a Phase 1 study in the U.S. The U.K. and South Africa variants have because they are more infectious and carry a higher viral load than other strains of the virus. Moderna's stock has gained 520.3% over the past 12 months, while the S&P 500 is up 15.6%.
4:24 a.m. Jan. 25, 2021 - By Jaimy Lee
CDC says doses of COVID-19 vaccines can be spaced out by up to 42 daysThe Centers for Disease Control and Prevention updated for vaccine administration to say that it's okay to space out the first and second doses of the currently available COVID-19 vaccines by up to 42 days, if necessary. The regulatory labels say that doses of the BioNTech SE and Pfizer Inc. vaccine should be spaced 21 days apart, while the second dose of Moderna Inc.'s 's vaccine is expected to be administered 28 days after the first dose. "However, if it is not feasible to adhere to the recommended interval, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be scheduled for administration up to 6 weeks (42 days) after the first dose," the CDC said. The United Kingdom has also said of its authorized vaccines, which include the AstraZeneca and University of Oxford vaccine in addition to the ones developed by BioNTech/Pfizer and Moderna, as needed. Over the past 12 months, BioNTech's stock has rallied 209.9%, Pfizer shares are down 3.1%, and Moderna's stock has soared 520.3%. The S&P 500 has gained 15.6% over the past year.
10:51 a.m. Jan. 22, 2021 - By Ciara Linnane
U.S. suffers another 4,000 deaths in a single day as experts welcome Fauci’s return to White House podium Biden calls on Americans to ‘mask up’ for the next 100 daysThe global tally for the coronavirus-borne illness COVID-19 climbed above 97.9 million on Friday and the U.S. death toll rose above 411,000, as experts welcomed the return to the White House podium of the nation’s leading infectious disease expert, after months of being sidelined by the previous administration.
8:50 a.m. Jan. 21, 2021 - By Ciara Linnane
Biden signs flurry of orders to tackle pandemic that has now cost more than 407,000 American lives Fauci addresses board of World Health Organization with promise that U.S. will join international response to crisisThe global case tally for the coronavirus-borne illness COVID-19 edged above 97 million on Thursday with the U.S. accounting for 24 million of those cases, as President Joe Biden wasted no time in implementing his plan to address a crisis that has caused the loss of more than 407,000 American lives.
9:00 a.m. Jan. 20, 2021 - By Ciara Linnane
Biden to overhaul U.S. pandemic management as death toll heads above 402,000 New president is expected to rejoin WHO, sign up for COVAX program and restore NSC-backed pandemic committeeThe global case tally for the coronavirus-borne illness COVID-19 climbed above 96.4million on Wednesday, and the U.S. death toll headed above 402,000 as President Joe Biden was inaugurated with plans to fully overhaul the U.S. approach to the pandemic.
11:14 a.m. Jan. 15, 2021 - By Jaimy Lee
CDC: New more infectious strain of the coronavirus likely to become dominant in the U.S. by MarchThe Centers for Disease Control and Prevention said Friday that a new more infectious strain of SARS-CoV-2 will likely become the most dominant form of the virus in the U.S. by March. The strain, B.1.1.7, was first identified by health officials in the United Kingdom in December. The CDC said in a new that enhanced genomic sequencing, in addition to vaccination and standard mitigation practices like mask-wearing and social distancing, will be needed to stem the spread of the new strain. President-elect Joe Biden announced Thursday that for a national genomic sequencing surveillance system, given that the U.S. is trailing other developing countries using this technology in their pandemic responses. "CDC's modeling data show that universal use of and increased compliance with mitigation measures and vaccination are crucial to reduce the number of new cases and deaths substantially in the coming months," the agency said. It also said the U.S. should conduct "strategic testing" of people without symptoms but who are at high-risk for contracting the virus. More than 70 people in 12 states are confirmed to have been infected with the new strain, as of Jan. 13, .
11:02 a.m. Jan. 15, 2021 - By Ciara Linnane
Global deaths from COVID-19 top 2 million as U.S. suffers most weekly fatalities since start of the pandemic Weekly deaths exceed CDC’s estimate for flu-related deaths for entire 2019-2020 season The global case tally for the coronavirus-borne illness COVID-19 climbed above 93 million on Friday and the death toll climbed above 2 million, with the U.S. leading all nations by cases and fatalities.
10:15 a.m. Jan. 12, 2021 - By Ciara Linnane
U.S. heads toward 23 million COVID-19 cases as three lawmakers test positive after Capitol lockdown News adds to fears that last week’s attack on the U.S. seat of government created two superspreader eventsThe number of confirmed global cases of the coronavirus-borne illness COVID-19 climbed above 91 million on Tuesday, and the U.S. case tally headed toward 23 million, as three Democratic lawmakers who were forced to shelter in place during last week’s attack on the Capitol tested positive for the virus.
1:30 p.m. Jan. 11, 2021 - By Ciara Linnane
U.S. tops 22 million cases of COVID-19 after adding record of more than 300,000 in a day ‘COVID remains out of control in the U.S.,’ analyst saysThe global case tally for the coronavirus illness COVID-19 rose above 90 million on Monday, and the U.S. topped 22 million confirmed cases, after setting a record for new cases in a single day of more than 300,000 on Friday.
10:37 a.m. Jan. 8, 2021 - By Ciara Linnane
More than 4,000 U.S. lives lost to COVID in single day, exceeding death toll from 9/11 attacks Numbers exceed even worst-case scenario forecasts of health experts as vaccine rollout continues to lag targetsThe U.S. set yet another record for the number of fatalities from the coronavirus-borne illness COVID-19 and recorded the highest number of new cases since the start of the outbreak, with the latest numbers exceeding even the worst case scenario forecasts of health experts.
10:39 a.m. Jan. 7, 2021 - By Ciara Linnane
U.S. counts record of almost 4,000 COVID-19 deaths in a day as virus continues to wreak havoc Experts fear the mob that stormed the U.S. Capitol on Wednesday may have created a superspreader event as few wore face masksAs the dramatic events in Washington, D.C. were unfolding Wednesday, the coroanvirus-borne illness COVID-19 continued to wreak havoc in the U.S., claiming a record of almost 4,000 American lives, the most in a single day since the start of the outbreak.
2:15 a.m. Jan. 7, 2021 - By Ciara Linnane
U.S. could see up to 150,000 more COVID-19 deaths by February as new strain takes hold, expert warns More infectious variant makes it even more crucial to get vaccine program on track after early disappointment, says Dr. Ashish JhaThe U.S. set a fresh record for hospitalizations with the coronavirus-borne illness COVID-19 on Wednesday, as experts said the new, far more infectious variant makes it even more crucial to get the nation’s so-far underwhelming vaccine program on track.
10:19 a.m. Jan. 5, 2021 - By Ciara Linnane
January will be worst month for U.S. pandemic so far with post-holiday travel cases seen surging U.S. sets fresh record for hospitalizations and Los Angeles County says a COVID-19 patient is dying every 15 minuteshe number of global cases of the coronavirus-borne illness COVID-19 edged toward 86 million on Tuesday and the U.S. set yet another record for hospitalizations, as experts warned that January will likely be the worst month of the pandemic so far due to a surge in new infections after holiday travel.
10:56 a.m. Jan. 4, 2021 - By Ciara Linnane
U.S. heads toward 21 million COVID-19 cases and 353,000 deaths as vaccine program continues to lag all targets ‘Last mile’ vaccine distribution has been far slower than required, ‘with millions of doses still sitting on the shelves,’ says Raymond James analystThe global case tally for the coronavirus-borne illness COIVID-19 climbed above 85 million on Monday, as the U.S. headed toward 21 million cases and 353,000 deaths, as the vaccine program continued to advance with fits and starts and to lag all early targets.
Browse topics:

Filter results by

Location

Us (443)

Europe (90)

Asia Pacific (79)

Eu (66)

China (56)

Latin America (18)

Link to MarketWatch's Slice.